InflaRx Seeks US Emergency Use Authorization for Treatment of Critically Ill COVID Patients

 

• Company also earns FDA Fast Track designation for vilobelimab to treat critically ill COVID-19 patients

• EUA submission based on Phase III results in critically ill COVID-19 patients, recently published in The Lancet Respiratory Medicine

• Request for EUA follows encouraging interactions with FDA in Type B meeting

• “Gohibic” conditionally accepted by FDA as proprietary name for vilobelimab

https://finance.yahoo.com/news/inflarx-submits-request-emergency-authorization-113000812.html